The Global Liver Institute (GLI) is an American non-profit organization based in Washington, D.C.
Funding
GLI has received funding from:[1]
- Allergan
- American Cancer Society (ACS)
- Amgen
- Astellas Pharma
- BioIVT
- Boehringer Ingelheim
- Bristol-Myers Squibb
- BTG
- Cancer Support Community (CSC)
- ChronWell
- Crown Bioscience
- CryerHealth
- CURE
- Einstein Healthcare Network
- Eisai
- Eli Lilly
- Enanta Pharmaceuticals
- EveryLife Foundation for Rare Diseases
- Exelixis
- Genentech
- GENFIT
- Georgetown University
- Gilead Sciences
- Hepatitis B Initiative of D.C., Maryland, and Virginia
- Inova
- Intercept Pharmaceuticals
- Johns Hopkins University School of Medicine
- Labcorp
- Madrigal Pharmaceuticals
- Mayo Clinic
- Merck
- Mirum Pharmaceuticals
- National Patient Advocate Foundation (NPAF)
- Novartis
- Novo Nordisk
- Nutristyle
- OncLive
- O'Neill Institute for National and Global Health Law
- ORGANIZE
- Perspectum
- Pfizer
- Pharmaceutical Research and Manufacturers of America (PhRMA)
- Promethera Biosciences
- ProSciento
- Regeneron Pharmaceuticals
- Targeted Oncology
- Travere Therapeutics
- Triage Cancer
- University of Pennsylvania Health System
- Zydus Lifesciences
External links
Who We Are. Global Liver Institute. Retrieved July 10, 2023, from https://web.archive.org/web/20230710042334/https://globalliver.org/who-we-are/ ↩︎
